Jump to content

Biomarker for Diffuse Scleroderma skin has been discovered!


Actelion says FDA accepts Macitentan for review.

  • Please log in to reply
No replies to this topic

#1 Joelf


    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,610 posts
  • Location:West Sussex

Posted 20 January 2013 - 12:02 AM

Actelion says FDA accepts Macitentan for review.

Actelion has submitted an FDA application for macitentan for the treatment of pulmonary arterial hypertension (PAH), a condition characterized by abnormally high blood pressure in the arteries of the lungs. The review is expected to take 12 months. Reuters. 12/14/12. (Also see: Pulmonary Hypertension and Macitentan)

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)